ANSA.it Economia

• Cabometyx^® in combination with Opdivo^® showed superior overall survival and doubled median progression-free survival and objective response rate versus sunitinib, and had a favorable safety profile
• Efficacy benefits were observed across key patient subgroups, including all International Metastatic Renal Cell Carcinoma Database Consortium risk and PD-L1 subgroups
• Patients treated with Cabometyx^® in combination with Opdivo^® reported significantly better health-related quality of life than those treated with sunitinib at most time points
• These data have been selected for presentation during Presidential Symposium and featured in official Press Programme at European Society for Medical Oncology Virtual Congress 2020

− Risultati importanti dalle analisi secondarie dello studio di fase 3 ALTA 1L supportano ulteriormente la solida efficacia intracranica di ALUNBRIG e il miglioramento della qualità della vita nel trattamento di prima linea di NSCLC ALK+

− I dati positivi del follow-up a 10 mesi dallo studio di fase 1/2 confermano i risultati precedentemente riportati su mobocertinib nei pazienti con NSCLC metastatico con mutazioni inserzionali dell'esone 20 dell'EGFR

• Le risposte confermate da un esame centrale indipendente comprendono 1 risposta completa, 12 risposte parziali e 33 risposte di malattia stabile per un tasso di risposta oggettivo pari al 14% e un controllo della malattia pari al 49%
• Le risposte sono state osservate indipendentemente dallo status del PD-L1, dalla presenza di metastasi epatiche o dallo stadio dell'HIV+
• La presentazione è disponibile on-demand nell'ambito del Congresso virtuale ESMO 2020
• POD1UM-303/InterAACT 2, uno studio clinico di fase 3 volto a valutare retifanlimab addizionato a chemioterapia in pazienti con carcinoma a cellule squamose del canale anale non operabile localmente ricorrente o metastatico è attualmente aperto e in fase di arruolamento dei pazienti.

− Key Results from Phase 3 ALTA 1L Sub-Analyses Further Support ALUNBRIG’s Strong Intracranial Efficacy and Enhanced Quality of Life in First-Line ALK+ NSCLC

− Positive 10-Month Follow-Up Data from Phase 1/2 Trial Reaffirm Mobocertinib’s Previously Reported Results in Patients with EGFR Exon20 Insertion+ Metastatic NSCLC

• Independent central review confirmed responses include 1 complete response, 12 partial responses and 33 stable disease for an objective response rate of 14% and disease control rate of 49%
• Responses were observed regardless of PD-L1 status, presence of liver metastases or HIV+ status
• Presentation is available on-demand as part of the ESMO Virtual Congress 2020
• POD1UM-303/InterAACT 2, a Phase 3 trial evaluating retifanlimab plus chemotherapy in patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal is now open and recruiting patients.

• Sigfox, the global 0G network and cloud provider for industrial data, announces a new strategic alliance with Cube Infrastructure Managers.
• Cube Infrastructure Managers brings together the Sigfox 0G network operators in Germany, Austria, Switzerland and Liechtenstein, through the acquisition of a majority stake in Heliot Europe and the acquisition of Sigfox Germany.
• This transaction will accelerate the deployment of IoT infrastructure, which is essential to the competitiveness and sustainable development of the European economy.

• Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs
• These results show no new safety signals associated with this increased dose regimen, potentially delaying the need for additional, more toxic second-line therapies
• The incidence of NETs is increasing, and are now among the fastest growing class of cancers worldwide, accounting for around 2% of all cancers¹

• Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF 435
• In addition Vifor Pharma obtains an earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity which could increase the total transaction value in excess of MCHF 500
• Closure of the transaction is expected within 30 days
• Divestment strengthens Vifor Pharma’s focus on becoming the global leader in iron deficiency, nephrology and cardio-renal therapies

Le società di consulenza globali Heidrick & Struggles, Egon Zehnder, 11 Private Equity Firms e importanti partner per la diversità partecipano all'impegno sempre più diffuso per la pubblicazione di opportunità nell'ambito dei consigli aziendali nella rete di professionisti gestita da Diligent

L’integrazione di AMPLIFY™ API Management e Microsoft Azure migliora l’esperienza del cliente in un mondo ibrido

L’azienda, specializza nello sviluppo di soluzioni per la rilevazione di dispositivi, sceglie la tecnologia di IP intelligence più avanzata nel settore per migliorare ulteriormente l’offerta dei suoi prodotti a livello globale

Integration of AMPLIFY™ API Management and Microsoft Azure enhances customer experience in a hybrid world

La piattaforma digitale interattiva presenterà le nuove collezioni degli stilisti

L’accordo permette all’Organizzazione della Nazioni Unite di usare l’intelligence territoriale per lo sviluppo di comunità sostenibili a livello globale

Global Search Firms Heidrick & Struggles, Egon Zehnder, 11 Private Equity Firms, and Key Diversity Partners Join Expanding Effort to Publish Board Opportunities in Diligent Director Network

Tower defense RPG Final Fate TD combines challenging strategy RPG gameplay with dazzling anime graphics